Selecta Biosciences Reports Second Quarter 2023 Financial Re

– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 –

Related Keywords

Watertown , Massachusetts , United States , Boston , Idexork Xork , Blaine Davis , Selecta Biosciences , Carsten Brunn , European Congress , Exchange Commission , Development Expenses , Company Imm , European Alliance Of Associations Rheumatology , Company Proprietary Treg , Company Board Of Directors , Chronic Refractory Gout In Partnership , Strategic Initiative Overview , Selecta Biosciences Inc , Nasdaq , Biologics License Application , Chief Executive Officer , Initiative Overview , Chronic Refractory Gout , Swedish Orphan Biovitrum , European Alliance , Proprietary Treg Selective , Through Potential , Investigational New Drug Enabling , Astellas Gene , Astellas Gene Therapies , Late Onset Pompe , Additional Pipeline , License Revenue , Administrative Expenses , Greater Boston , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Comprehensive Income , Region ,